As an example of well-stablished interactions, nilotinib, a second-generation BCR-ABL tyrosine kinase inhibitor of Chronic Myeloid Leukemia (CML), was associated with known targets such as BCR-ABL1, KIT, and PDGFR [20]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.